Delaney Dennis R buys $1.6 Million stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Delaney Dennis R scooped up 120 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 27, 2016. The investment management firm now holds a total of 40,398 shares of Abbott Laboratories which is valued at $1.6 Million.Abbott Laboratories makes up approximately 3.42% of Delaney Dennis R’s portfolio.

Other Hedge Funds, Including , Puzo Michael J boosted its stake in ABT in the latest quarter, The investment management firm added 6,450 additional shares and now holds a total of 45,291 shares of Abbott Laboratories which is valued at $1.8 Million. Abbott Laboratories makes up approx 1.18% of Puzo Michael J’s portfolio.Hm Payson Co boosted its stake in ABT in the latest quarter, The investment management firm added 17,367 additional shares and now holds a total of 776,244 shares of Abbott Laboratories which is valued at $29.2 Million. Abbott Laboratories makes up approx 1.52% of Hm Payson Co’s portfolio. Springbok Capital Management added ABT to its portfolio by purchasing 1,454 company shares during the most recent quarter which is valued at $54,670. Abbott Laboratories makes up approx 0.01% of Springbok Capital Management’s portfolio.Re Advisers Corp boosted its stake in ABT in the latest quarter, The investment management firm added 1,203,000 additional shares and now holds a total of 1,614,000 shares of Abbott Laboratories which is valued at $60.7 Million. Abbott Laboratories makes up approx 1.08% of Re Advisers Corp’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.61% at $38.93 with 1,02,02,655 shares getting traded on Tuesday. Post opening the session at $39.12, the shares hit an intraday low of $38.92 and an intraday high of $39.28 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.